Join Professor Joaquim Mullol for a discussion of the emerging definition of clinical remission in CRSwNP and the need for long-term disease control for patients with severe CRSwNP.
Director of the Rhinology Unit & Smell Clinic, Department of Otorhinolaryngology | Hospital Clinic, Barcelona, Spain; Professor of Research and Head of the Laboratory of Clinical and Experimental Respiratory Immunoallergy | August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain | Head of Research Group at Biomedical Research Network on Respiratory Diseases (CIBERES) | Carlos III Institute of Health, Barcelona, Spain
See author’s profileADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.
All rights reserved.
MAT-GLB-2302957 v3.0 11/2023
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.